2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Breast Neoplasms
628
Stomach Neoplasms
75
Neoplasm Metastasis
59
Neoplasms
39
HER2-positive Breast Cancer
33
Breast Neoplasms, Male
30
Colorectal Neoplasms
28
Brain Neoplasms
25
Carcinoma, Non-Small-Cell Lung
21
Inflammatory Breast Neoplasms
20
Esophageal Neoplasms
20
Pancreatic Neoplasms
13
Triple Negative Breast Neoplasms
12
Lung Neoplasms
11
Endometrial Neoplasms
11
Ovarian Neoplasms
10
Colonic Neoplasms
10
Urinary Bladder Neoplasms
9
Rectal Neoplasms
9
Prostatic Neoplasms
9
Cardiotoxicity
8
Adenocarcinoma
8
Salivary Gland Neoplasms
7
Gallbladder Neoplasms
7
Breast Diseases
7
Biliary Tract Neoplasms
7
Adenocarcinoma Of Esophagus
7
Uterine Cervical Neoplasms
6
Squamous Cell Carcinoma of Head and Neck
6
Sarcoma
6
Interventions
trifluridine tipiracil drug combination
1
Trastuzumab
1
Panitumumab
1
Oxaliplatin
1
Nivolumab
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Dihydropyrimidine Dehydrogenase Deficiency
×
Trastuzumab
×
Clear all
NCT06245356
2025-12-10
TRIFLUOX-DP
UNICANCER
Phase 2
Recruiting
73 enrolled